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ABSTRACT  27 
Subversion of innate immunity by oncoviruses, such as human papillomavirus (HPV), favors 28 
carcinogenesis because the mechanism(s) of viral immune evasion can also hamper cancer 29 
immunosurveillance. Previously, we demonstrated that high-risk (hr) HPVs trigger simultaneous 30 
epigenetic silencing of multiple effectors of innate immunity to promote viral persistence. Here, we 31 
expand on those observations and show that the HPV E7 oncoprotein upregulates the H3K9-32 
specific methyltransferase, whose action shuts down the host innate immune response. Specifically, 33 
we demonstrate that SUV39H1 contributes to chromatin repression at the promoter regions of the 34 
viral nucleic acid sensors RIG-I, cGAS and the adaptor molecule STING in HPV-transformed cells. 35 
Inhibition of SUV39H1 leads to transcriptional activation of these genes, especially RIG-I, 36 
followed by increased IFN and 1 production after poly(dA:dT) or RIG-I agonist M8 transfection, 37 
Collectively, our findings provide new evidence that the E7 oncoprotein plays a central role in 38 
dampening host innate immunity and raise the possibility that targeting the downstream effector 39 
SUV39H1 or the RIG-I pathway may be a viable strategy to treat viral and neoplastic disease. 40 
 41 
IMPORTANCE  42 
High-risk HPVs are major viral human carcinogens responsible for approximately 5% of all human 43 
cancers. The growth of HPV-transformed cells depends on the ability of viral oncoproteins to 44 
manipulate a variety of cellular circuits, including those involved in innate immunity. Here, we 45 
show that one of these strategies relies on E7-mediated transcriptional activation of the chromatin 46 
repressor SUV39H1, which then promotes epigenetic silencing of RIG-I, cGAS and STING genes, 47 
thereby shutting down interferon secretion in HPV-transformed cells. Pharmacological or genetic 48 
inhibition of SUV39H1 restored the innate response in HPV-transformed cells, mostly through 49 
activation of RIG-I signaling. We also show that IFN production upon transfection of poly(dA:dT) 50 
or the RIG-I agonist M8 predominantly occurs through RIG-I signaling. Altogether, the reversible 51 
nature of the modifications associated with E7-mediated SUV39H1 upregulation provides a 52 
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rationale for the design of novel anticancer and antiviral therapies targeting these molecules. 53 
 54 
INTRODUCTION  55 
Human papillomaviruses (HPVs) are circular double-stranded DNA viruses with a small 56 
genome of approximately 8 kb. Over 200 types of HPV have been identified and classified 57 
according to whether they infect cutaneous or mucosal epithelium 58 
(http://www.ictv.global/report/papillomaviridae; 1-3). Cancer-causing HPVs are classified as “high-59 
risk” (hr) types, among which the most commonly found are the α-genotypes HPV16 and HPV18, 60 
well-known to be the causative agents of cervical and anogenital cancers and heavily implicated in 61 
head and neck cancers (4, 5).  62 
The development of HPV-associated cancers relies on the expression of two oncoproteins, 63 
E6 and E7, which are the only viral genes consistently found in these tumors (6, 7).  Although these 64 
oncoproteins do not exhibit enzymatic function, their transforming activity is mediated primarily 65 
through protein-protein interactions that ultimately favor the formation of a replication-competent 66 
environment that eventually leads to cancer (8). Specifically, hrHPV E6 targets the p53 tumor 67 
suppressor protein for degradation, thereby preventing p53 from mediating cell cycle arrest and 68 
apoptosis in response to cellular stress signals (9, 10). In contrast, hrHPV E7 promotes degradation 69 
of the retinoblastoma tumor suppressor (pRb) protein, thus eliciting E2F-mediated transcriptional 70 
activation of S-phase genes (2, 10).  Importantly, both HPV E6 and E7 trigger epigenetic changes in 71 
chromatin by altering the expression or the enzymatic activity of a number of epigenetic modifiers, 72 
such as histone deacetylases, histone demethylases, histone acetyltransferases, and histone 73 
methyltransferases (11-19). Concomitantly, the oncogenic stimuli triggered by HPV oncoproteins 74 
cause host cells to mount an antiviral innate immune response. Nonetheless, HPVs have evolved 75 
strategies to subvert antiviral immunity in order to complete their viral life cycle and persist in the 76 
host cell (20-24).  77 
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In recent studies, we demonstrated that in NIKSmcHPV18 keratinocytes carrying episomal 78 
HPV18, as well as in HeLa cells harboring an integrated HPV18 genome, induction of both IFN 79 
and IFN1 by DNA ligands is significantly impaired compared to parental cells (25). Furthermore, 80 
we found that downregulation of stimulator of IFN genes (STING), cyclic GMP-AMP synthase 81 
(cGAS) and retinoic acid-inducible gene I (RIG-I) mRNA levels occurs at the transcriptional level 82 
through a novel epigenetic silencing mechanism, based on the accumulation of repressive 83 
heterochromatin marks, especially H3Lys9me2 (H3K9me2), at the promoter region of these genes 84 
(25). The incorporation of histone marks in chromatin represents a dynamic balance between 85 
enzymes depositing the mark (writers) and other enzymes removing it (erasers) (26). In this regard, 86 
SUV39H1, the human homolog of the Drosophila Su(var)3-9 histone methyltransferase, is the 87 
prime histone code “writer” responsible for histone H3Lys9 trimethylation (H3K9me3), which 88 
marks chromatin in a “closed” conformation (27, 28).  89 
In this study, we show that SUV39H1 is involved in epigenetic silencing of RIG-I, cGAS 90 
and STING genes in hrHPV-transformed cells. Importantly, pharmacological or genetic inhibition 91 
of SUV39H1 restored the innate immune response to exogenous DNA, as reflected by the 92 
production of both IFN and 1. SUV39H1 upregulation was dependent on E7 protein expression, 93 
as demonstrated by either loss or gain of function experiments. In particular, we show that loss of 94 
E7 expression in both HeLa and CaSki cells significantly enhanced IFN production upon 95 
poly(dA:dT) or RIG-I agonist M8 transfection, predominantly through RIG-I signaling.   96 
 97 
RESULTS 98 
SUV39H1 increases heterochromatin formation at the promoter regions of RIG-I, 99 
cGAS and STING genes in HPV-transformed cells. To determine which histone modifier 100 
enzyme was responsible for HPV-driven epigenetic modifications of the innate immune response, 101 
RNA extracts from NIKS, NIKSmcHPV18 or HeLa cells were analyzed for mRNA expression 102 
levels of the three major H3K9-specific methyltransferases, G9a-like protein (Glp1), G9a, and 103 
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SUV39H1 (27). CaSki cells were also included in our analysis because they harbor an integrated 104 
HPV16 genome, another high-risk alpha genotype (29, 30). As shown in Fig. 1A, SUV39H1 105 
mRNA levels were significantly upregulated in HPV-transformed vs NIKS cells, especially in HeLa 106 
and CaSki cells (8- and 6-fold, respectively), while Glp1 and G9a mRNA levels were only 107 
marginally modulated. A similar increase in SUV39H1 protein was also seen in Western blot 108 
analysis (Fig. 1B).  109 
To further define the mechanistic role of SUV39H1, we assessed mRNA and protein 110 
expression levels of RIG-I, cGAS and STING genes in cells treated in the presence or absence of 111 
chaetocin, a pharmacological inhibitor of H3K9me3-specific methyltransferase (31, 32). For these 112 
experiments, HeLa and CaSki cells were chosen because they displayed higher basal levels of 113 
SUV39H1 protein, compared to NIKSmcHPV18. As shown in Fig. 1C, RIG-I mRNA levels were 114 
significantly upregulated (15-fold) in both HeLa and CaSki cells after 24 h of chaetocin treatment, 115 
while cGAS and STING mRNA expression levels were also increased but to a lesser extent (5- and 116 
3-fold in HeLa cells; 4- and 2.4-fold in CaSki cells, respectively). In contrast, NIKS cells, with low 117 
basal expression levels of SUV39H1 (Fig. 1A and B), did not show any significant variation in gene 118 
expression following chaetocin treatment (Fig. 1C). The same trend was also observed at the 119 
protein level for all three genes (Fig. 1D). Consistent with the aforementioned transcriptional 120 
activation, a significant decrease in H3K9me2 and H3K9me3 marks (i.e. repressive chromatin) 121 
associated with the promoter regions of RIG-I, cGAS and STING was observed by ChIP assay in 122 
lysates of chaetocin-treated HeLa (Fig. 1E) and CaSki cells (Fig. 1F). These findings indicate that 123 
the H3K9-specific methyltransferases SUV39H1, whose expression is significantly upregulated in 124 
HPV-transformed cells, is involved in the modeling of the repressive chromatin structure 125 
surrounding the RIG-I, cGAS and STING promoters. Furthermore, pharmacological inhibition of 126 
SUV39H1 decreased the promoter-bound heterochromatin marks H3K9me2 and H3K9me3, likely 127 
switching the chromatin structure from a repressive to a permissive state.  128 
Pharmacological and genetic inhibition of SUV39H1 activity restores IFN production 129 
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in HPV-transformed cells upon poly(dA:dT) stimulation. Next, to determine if the drug-induced 130 
gain-of-function of RIG-I, cGAS and STING increased IFN production upon stimulation with the 131 
DNA agonist poly(dA:dT), NIKS, HeLa, and CaSki cells were treated with chaetocin or vehicle for 132 
6 h, transfected with poly(dA:dT) for 24 h, and supernatants harvested to assess IFN production. 133 
Consistent with the results above, IFN production was significantly higher in both chaetocin-134 
treated HeLa and CaSki cells compared to vehicle- or poly(dA:dT)-treated cells (Fig. 2A, left 135 
panel); a similar trend was also observed for IFN1 (Fig. 2A, right panel). Consistent with the 136 
observed lack of SUV39H1 upregulation in NIKS cells (Fig. 1A and B), chaetocin treatment did not 137 
lead to a significant change in IFN production after poly(dA:dT) transfection (Fig. 2A). 138 
We next used a lentiCRISPR-based approach to disrupt SUV39H1 in both HeLa and CaSki 139 
cells and confirmed protein loss by immunoblotting (Fig. 2B). Accordingly, H3K9me3 expression 140 
levels were decreased in SUV39H1 KO cells vs. control cells (4- and 2.5-fold in HeLa and CaSki, 141 
respectively), while H3K27me3 levels remained unchanged (Fig. 2B). Consistent with the results 142 
observed in chaetocin-treated cells (Fig. 1C and D), upregulation of RIG-I mRNA expression levels 143 
upon poly(dA:dT) transfection was higher in SUV39H1 KO cells when compared to parental cells 144 
(2-fold in both HeLa and CaSki cells) (Fig. 2C). In contrast, poly(dA:dT) transfection failed to 145 
significantly induce both cGAS and STING mRNA levels in cells lacking SUV39H1 (Fig. 2C). The 146 
same trend was confirmed at the protein level, where RIG-I was upregulated by 1.5-fold in both 147 
poly(dA:dT)-transfected HeLa and CaSki cells compared to their normal counterparts similarly 148 
treated (Fig. 2D).  149 
Next, cells were treated with poly(dA:dT) to assess the innate immune response in terms of 150 
IFN released in the culture supernatants. As shown in Figure 2E, IFN production increased by 4- 151 
and 2-fold in poly(dA:dT)-treated SUV39H1 KO HeLa and CaSki cells, respectively, in 152 
comparison with their stimulated parental cells. A similar trend was observed for IFN1 in both cell 153 
lines.  Altogether, this observation demonstrates that pharmacological or genetic inhibition of 154 
SUV39H1 expression leads to modifications in the chromatin structure of the RIG-I, cGAS and 155 
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STING promoters, switching them from a repressive to a permissive status. The recovery of gene 156 
expression, especially in the case of RIG-I, was then able to restore the innate immune response to 157 
DNA ligands, as judged by the increased production of IFNs. 158 
HPV E7 regulates SUV39H1 expression levels. To determine which viral oncoprotein was 159 
responsible for the increase in SUV39H1 activity in hrHPV-transformed cells, E6 and E7 proteins 160 
were either silenced in HeLa and CaSki cells or overexpressed in HEK293 cells. Because E6 and 161 
E7 are transcribed as a single bicistronic pre-mRNA undergoing extensive alternative splicing, we 162 
used an siRNA targeting the intron 1 region (siE6/E7#1), only present in unspliced RNA, which 163 
would have allowed us to knock down E6 expression in HeLa cells, while only marginally affecting 164 
E7 expression (Fig. 3A). In addition, an exon 2-specific siRNA (siE6/E7#2) was also used to 165 
simultaneously disrupt E6 and E7 expression in the same cell (33). As shown in Fig. 3B, SUV39H1 166 
protein levels were downregulated in siE6/E7#2-transfected HeLa cells but not in cells silenced with 167 
siE6/E7#1, unable to inhibit E7 expression, or siCtrl, suggesting that E7 but not E6 regulates 168 
SUV39HI protein expression in these cells. Consistent with SUV39H1 inhibition, total H3K9me3 169 
protein levels were only reduced in E7-silenced cells (Fig. 3B). Assessment of the mRNA 170 
expression levels of the SUV39H1 gene confirmed that depletion of HPV oncoproteins, mainly E7 171 
in the case of HPV18, determined a significant transcriptional inhibition of this gene (Fig. 3C).  172 
The same siRNA sets were also used in CaSki cells, in which selected ablation was however 173 
not achieved given that both siE6/E7#1 and siE6/E7#2 were able to knock down both oncoproteins, 174 
albeit to different extents (Fig. 3B). As expected, transfection of either siE6/E7#1 or siE6/E7#2, both 175 
capable of shutting down E7 protein expression, but not siCtrl, resulted in downregulation of 176 
SUV39H1 protein levels. Fittingly, H3K9me3 protein expression was significantly inhibited in both 177 
E7-silenced cells in comparison with siCtrl-transfected cells. 178 
Altogether, these findings indicate that E7 plays a major role in SUV39H1 transcriptional 179 
activation and in the ensuing epigenetic silencing of the innate response. Accordingly, mRNA 180 
expression levels of RIG-I, cGAS and STING genes were significantly increased after poly(dA:dT) 181 
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transfection in siE6/E7#2-silenced HeLa cells (Fig. 3D, upper panels). Of note, transcriptional 182 
activation of the RIG-I gene was induced 70-fold in unstimulated and 15-fold in siE6/E7#2-183 
transfected HeLa cells (Fig. 3D, upper panels). A similar trend was also observed in E6/E7-silenced 184 
CaSki cells: 9-fold induction in unstimulated and 110-fold induction in stimulated siE6/E7#1-185 
transfected CaSki cells (Fig. 3D, lower panels). Importantly, siE6/E7#1 generally led to a more 186 
robust transcriptional activation of all three genes when compared to cells transfected with 187 
siE6/E7#2, in good agreement with the stronger SUV39H1 inhibition shown in Figure 3A and B.  188 
Consistent with the restoration of PRR expression, IFN and IFN1 production was 189 
significantly higher in siE6/E7#2- vs. siCtrl-transfected HeLa cells following poly(dA:dT) 190 
stimulation (18-fold for IFN and 10-fold for IFN1 respectively) (Fig. 3E, upper panels). IFN 191 
production was also significantly enhanced in siE6/E7#1-transfected CaSki cells stimulated with 192 
poly(dA:dT) compared to similarly treated siCtrl cells (140-fold for IFN and 2.5-fold for IFN1 193 
respectively) (Fig. 3E, lower panels).  194 
In parallel, HEK293 cells expressing either E6 or E7 from HPV18 or HPV16 were evaluated 195 
for SUV39H1 expression and global H3K9 trimethylation. Interestingly, SUV39H1 expression was 196 
increased in all E7-expressing cells compared to control cells (2- and 2.4-fold induction in HEK293 197 
cells expressing HPV18 and HPV16, respectively) (Fig. 3F), while SUV39H1 expression was 198 
unchanged in E6-expressing cells. Consistently, E7 but not E6, reproducibly increased total 199 
H3K9me3 marks (Fig. 3F). Furthermore, SUV39H1 was upregulated at the mRNA level in E7-200 
expressing cells, indicating that the induction occurred at the transcriptional level (Fig. 3G). Lastly, 201 
poly(dA:dT)-mediated IFN and IFN1 production was significantly inhibited in both HPV18 E6- 202 
and E7-expressing cells, although to much higher extent in E7- vs. E6-expressing cells (Fig. 3H, 1st 203 
and 2nd panels). By contrast, a clear-cut picture emerged in the case of HPV16, where only the E7 204 
protein significantly downregulated the release of both IFN and IFN1 upon poly(dA:dT) 205 
transfection as compared to control cells (Fig. 3H, 3rd and 4th panels).  206 
RIG-I is essential to regain the innate immune response in hrHPV-transformed cells. 207 
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To further test the hypothesis that RIG-I activation in response to E7-mediated downregulation of 208 
SUV39H1 is responsible for restoration of IFN inducibility, we asked whether knock-down of RIG-209 
I expression by lenti-CRISPR would prevent IFN gene upregulation and protein secretion in HeLa 210 
and CaSki cells. RIG-I disruption (RIG-I KO) was confirmed by immunoblotting under basal 211 
conditions or upon poly(dA:dT) transfection (Fig. 4A). In addition, cells were also stimulated with 212 
the sequence-optimized 5’pppRNA RIG-I specific agonist M8 (34-36). IFN transcriptional 213 
activation and secretion was then measured under basal conditions or in E6/E7-silenced cell in the 214 
presence or absence of the aforementioned stimuli (Fig. 4B and C). Notably, M8 turned out to be a 215 
much stronger IFN inducer than poly(dA:dT) in either cell line, especially in the case of IFN. 216 
Similar to what observed for poly(dA:dT), M8-treatment of E6/E7-depleted cells induced higher 217 
levels of both IFN and IFN1 at either the mRNA or protein levels as compared to wild type  218 
(WT) cells. Consistent with the results reported in Fig. 3D, E7 silencing by siE6/E7#2 in HeLa or 219 
siE6/E7#1 in CaSki re-established agonist-mediated IFN and IFN1 transcription and secretion 220 
(Fig. 4B and C, respectively). In contrast, IFN inducibility in response to either agonist in RIG-I 221 
KO HeLa failed to restore, indicating that RIG-I is required for IFN induction in HPV-transformed 222 
cells. Intriguingly, siE6/E7#1-transfected RIG-I KO CaSki cells displayed a significant reduction in 223 
IFN production by M8 in comparison with siCtrl-transfected or siE6/E7#1-transfected WT CaSki 224 
cells, especially with regard to IFN(Fig. 4C, lower panels). On the other hand, following 225 
poly(dA:dT) transfection, siE6/E7#1-treated RIG-I KO CaSki cells showed levels of IFN/IFN1 226 
secretion comparable to those observed in treated WT CaSki cells (Fig. 4C, lower panels), implying 227 
that the absence of RIG-I signaling  might be compensated by the cGAS-STING pathway.  228 
Similar results were obtained by directly silencing the SUV39H1 gene in both parental and 229 
RIG-I KO cells (Fig. 4D). Once again, M8-mediated induction of IFN and IFN1 secretion was 230 
significantly enhanced in SUV39H1-silenced WT HeLa cells when compared to that of parental 231 
cells and more abundant than that observed in poly(dA:dT)-transfected cells (Fig. 4D, upper 232 
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panels). A similar trend was observed in siSUV39H1-transfected WT CaSki cells for IFN1 in 233 
response to poly(dA:dT) or M8 transfection (Fig. 4D, lower right panel). In the case of IFNFig. 234 
4D, lower left panel)the enhancement in siSUV39H1-transfected WT CaSki cells was more 235 
evident upon poly(dA:dT) transfection than M8 transfectionConsistent with the results shown in 236 
Fig. 4C (upper panels), in RIG-I-KO HeLa cells, IFN production was almost abolished in response 237 
to either poly(dA:dT) or M8 transfection; in siSUV39H1 RIG-I KO CaSki cells the activity of M8 238 
was dramatically reduced, whereas that of poly(dA:dT)-treated cells remained similar to that 239 
observed in siSUV39H1-transfected WT CaSki cells stimulated with poly(dA:dT) (Fig. 4D, lower 240 
panels).  241 
Altogether, these findings clearly indicate that the RIG-I pathway plays a functional role in 242 
IFN production in hrHPV-transformed cells. Furthermore, RIG-I signaling can be substantially 243 
upregulated by inhibiting either E7 or SUV39H1 expression. 244 
 245 
DISCUSSION 246 
 We recently reported that downregulation of RIG-I, cGAS and STING mRNA levels in 247 
hrHPV-harboring cells occurs at the transcriptional level through a novel epigenetic silencing 248 
mechanism, as shown by the presence of repressive heterochromatin marks at the promoter region 249 
of these genes (25). In the present study, we expand on those findings and show that in hrHPV-250 
transformed cells the increase in the repressive H3K9me2 and H3K9me3 marks is achieved through 251 
transcriptional induction of the H3K9-specific methyltransferase SUV39H1 (37). Specifically, we 252 
demonstrate that both pharmacological inhibition and gene silencing of SUV39H1 negatively 253 
affects the binding of H3K9me2 and H3K9me3 to the promoter region of RIG-I, cGAS and STING 254 
genes. The reduction of these two repressive marks at the promoter regions of the aforementioned 255 
genes was closely followed by gene transcriptional activation even in the absence of any exogenous 256 
stimulus. When SUV39H1 KO cells were treated with poly(dA:dT), the release of both IFN and 257 
IFN1 was significantly increased when compared to stimulated parental cells. Of note, the impact 258 
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of SUV39H1 activity on chromatin structure in HeLa cells harboring an integrated HPV18 was 259 
similar to that observed in CaSki cells containing an integrated HPV16, indicating that these two 260 
high-risk genotypes, accounting for the majority of HPV-related cancers (2), have developed 261 
evolutionarily conserved strategies in order to epigenetically overturn key players of the innate 262 
immune response.  263 
We also demonstrate that SUV39H1 upregulation is predominantly dependent on E7 protein 264 
expression, as demonstrated by either loss- or gain-of-function experiments. In particular, we show 265 
that loss of E7 expression in both HeLa and CaSki cells boosts the innate immune response through 266 
inhibition of SUV39H1 activity and transcriptional activation of genes upstream of the IFN 267 
cascade, especially RIG-I, which is followed by a substantial increase in IFN production upon 268 
poly(dA:dT) transfection.  269 
The importance of the RIG-I pathway in hrHPV-transformed cells also emerged when we 270 
used a strong RIG-I agonist M8 (34-36). Under basal conditions, M8 treatment of HeLa and CaSki 271 
cells was sufficient to achieve robust IFN production compared to poly(dA:dT)-stimulated cells, 272 
indicating that the host immune response was strictly dependent on the intrinsic performance of the 273 
agonist. Consistent with the results obtained in poly(dA:dT)-transfected cells, this induction was 274 
further enhanced in SUV39H1- or E7-depleted cells.  Knock-down of the RIG-I gene in hrHPV-275 
transformed cells ablates IFN induction after M8 but not poly(dA:dT) transfection, further 276 
confirming that inhibition of SUV39H1 activity preferentially rescues the RIG-I pathway rather 277 
than the cGAS-STING pathway. 278 
Collectively, these findings demonstrate that drug-targeted activation of the RIG-I signaling 279 
pathway may be a feasible option to trigger the innate immune response in HPV-transformed cells, 280 
which could potentially improve the effectiveness of existing anticancer therapies (38-44).  In 281 
summary, the present study describes a novel mechanism whereby impairment of the innate 282 
immune response in hrHPV-transformed cells occurs through E7-mediated transcriptional down-283 
regulation of RIG-I, cGAS and STING and is dependent on SUV39H1 activity. As summarized in 284 
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Fig. 5, our findings show an unprecedented role of SUV39H1 methyltransferase in switching the 285 
chromatin status from permissive to repressive, which in turn dampens the innate immune response 286 
in hrHPV-transformed cells. 287 
 288 
MATERIALS AND METHODS 289 
Cell culture, plasmids, transfection and treatments. The spontaneously immortalized 290 
human keratinocyte cell line NIKS (Stratatech Corporation) were cultured in the presence of J2 3T3 291 
fibroblast feeders as previously described (45). HeLa and HEK293 cells were grown in DMEM 292 
(Sigma-Aldrich), and CaSki cells in RPMI (Thermo Fisher Scientific), both supplemented with 293 
10% FBS (Sigma-Aldrich). NIKSmcHPV18 cells, stably harboring a high viral load of HPV18 294 
episomal genomes, were obtained and cultured as previously described (25).  295 
Chaetocin (150 nM) was obtained from Sigma-Aldrich. Poly(dA:dT) (1.25 µg/mL) (InvivoGen) 296 
was transfected into cells using Lipofectamine 3000, according to the manufacturer’s instruction 297 
(Thermo Fisher Scientific). M8 5’pppRNAs (100 ng/mL) was generated as previously described 298 
(35) and transfected using Lipofectamine RNAiMax transfection reagent as recommended by the 299 
manufacturer (Thermo Fisher Scientific). 300 
HeLa and CaSki cells were transfected with siRNA using Lipofectamine RNAiMax transfection 301 
reagent (Invitrogen). The following siRNAs were used: SUV39H1 (M-009604-02-0005, 302 
siGENOME SMARTpool siRNA), and control siRNA (D-001206-13-05, siGENOME Non-303 
Targeting siRNA Pool) were purchased from Dharmacon; siRNAs against RIG-I and E6/E7#1 304 
HPV18 were synthesized by Dharmacon, whereas siRNA against E6/E7#2 HPV18, E6/E7#1 HPV16, 305 
and E6/E7#2 HPV16 were synthesized by Sigma-Aldrich. E6/E7#1 HPV18 siRNA sequences were 306 
kindly provided by Lawrence Banks and available through him (46). The siRNA sequences are 307 
available upon request.     308 
HPV16 and HPV18 E6 or E7 genes were sub-cloned into pCI-neo mammalian expression vector 309 
(Promega) within compatible SalI/ EcoRI or XbaI/EcoRI restriction enzyme sites, respectively. The 310 
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primer sequences are available upon request. All constructs were sequenced (Eurofins), and 311 
overexpression was confirmed by Western blot analysis. HEK293 cells were transiently transfected 312 
with pCI-neo vector expressing HPV16 or HPV18 E6, E7, or empty vector control (1 μg) using 313 
Lipofectamine 3000 according to the manufacturer’s instructions (Thermo Fisher Scientific). 314 
Quantitative nucleic acid analysis. Real-time quantitative reverse transcription (qRT)-PCR 315 
analysis was performed on a CFX96tm Real Time System (Bio-Rad Laboratories Srl). Total RNA 316 
was extracted using TRI Reagent (Sigma-Aldrich), and 1 μg was retrotranscribed using iScript 317 
cDNA Synthesis kit (Bio-Rad Laboratories Srl). Reverse-transcribed cDNAs were amplified in 318 
duplicate using SensiFast SYBR (Bioline) for cellular genes. The glyceraldehyde 3-phosphate 319 
dehydrogenase (GAPDH) housekeeping gene was used to normalize for variations in cDNA levels. 320 
The reaction conditions consisted of a 30 s at 95°C enzyme activation cycle, 40 cycles of 10 s 321 
denaturation at 95°C, and 10 s annealing at 60°C. The primer sequences are available upon request. 322 
Immunoblotting.  Whole-cell protein extracts were prepared and subjected to immunoblot 323 
analysis as previously described (47). Nuclear acid extracts were obtained resuspending cell pellets 324 
in 200 μl ice-cold lysis buffer (10mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 325 
and 200 mM HCl supplemented with protease (Sigma-Aldrich) and phosphatase inhibitor cocktail 326 
(Active Motif). Cells were kept on ice for 30 min, and then the histone-enriched supernatants were 327 
collected by centrifugation at 4°C. Samples were subsequently precipitated with eight volumes of 328 
acetone overnight, centrifuged, air dried, and pellets were resuspended in deionized water. 329 
The following antibodies were used: rabbit monoclonal antibody anti-SUV39H1 (#702443; Thermo 330 
Fisher Scientific, diluted 1:1000), rabbit polyclonal antibodies anti-cGAS (HPA031700; Sigma-331 
Aldrich, diluted 1:500), RIG-I (06-1040; Merck Millipore, diluted 1:10000), anti-H3K9me3 (07-332 
442; Merck Millipore, diluted 1:500), anti-H3K27me3 (07-449; Merck Millipore, diluted 1: 20000), 333 
anti-HPV18 E6 (GTX132687;  GeneTex, diluted 1:250), anti-HPV18 E7 (GTX133412; GeneTex, 334 
diluted 1:500), anti-HPV16 E6 (GTX32686; GeneTex, diluted 1:500), anti-HPV16 E7 335 
(GTX133411; GeneTex, diluted 1:500) or mouse monoclonal antibody (MAb) anti-STING 336 
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(MAB7169; R&D Systems, 1:1500). Mab against α-tubulin (39527; Active Motif, diluted 1:4000) 337 
and rabbit antibody against unmodified histone H3 (06-755; Merck Millipore, diluted 1:15000) 338 
were used as a control for protein loading. Immunocomplexes were detected using sheep anti-339 
mouse or donkey anti-rabbit immunoglobulin antibodies conjugated to horseradish peroxidase 340 
(HRP) (GE Healthcare Europe GmbH) and visualized by enhanced chemiluminescence (Super 341 
Signal West Pico; Thermo Fisher Scientific). Images were acquired, and densitometry of the bands 342 
was performed using Quantity One software (version 4.6.9; Bio-Rad Laboratories Srl). 343 
Densitometry values were normalized using the corresponding loading controls. 344 
ChIP assay. ChIP assays were performed as previously described (45). 345 
Immunoprecipitation was performed with 3 µg of unmodified histone H3 (06-755), dimethyl-346 
histone H3 (Lys4; 07-030), dimethyl-histone H3 (Lys9; 07-441), trimethyl-histone H3 (Lys9; 07-347 
442), and trimethyl-histone H3 (Lys27; 07-449) antibodies, all purchased from Merck Millipore 348 
(Merck Millipore SpA). Threshold cycle (CT) values for the samples were equated to input CT 349 
values to provide percentages of input for comparison, and these were normalized to the enrichment 350 
level of unmodified histone H3 for each cell line. The primers used to amplify RIG-I, cGAS, and 351 
STING promoters are available upon request. 352 
ELISA assay.  The cytokines secreted in the culture supernatants were analyzed using 353 
Single Analyte Human ELISA kits for IFNβ (DY814-05; DuoSet ELISA Human IFNβ, R&D 354 
Systems) and IFNλ1 (DY7246; DuoSet ELISA Human IL-29/IFNλ1, R&D Systems) according to 355 
the manufacturer’s instructions. All absorbance readings were measured at 450 nm using a Victor 356 
X4 Multilabel Plate Reader (Perkin Elmer). 357 
Generation of SUV39H1 and RIG-I knockout HeLa and CaSki cells. SUV39H1 or RIG-358 
I (DDX58, DExD-Hbox helicase 58) knockout cells were generated with CRISPR/Cas9 technology 359 
using single guide RNA (sgRNA) obtained from Applied Biological Materials Inc. (All-in-One 360 
Lentivectors: cat. No. K2317005_SUV39H1; K0575405_DDX58; and K010_ scrambled sgRNA). 361 
To produce viral particles, HEK293T cells were transfected with an All-in-One Lentivector set 362 
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encoding Cas9 and SUV39H1, DDX58 or scrambled sgRNAs alongside 2nd Generation Packaging 363 
System Mix (Applied Biological Materials, Inc.) using Lipofectamine 2000 (Invitrogen). Viral 364 
supernatants were harvested at 72 h post-infection and used to transduce cells by infection in the 365 
presence of 8 mg/ml polybrene. Transduced HeLa or CaSki cells were selected with puromycin (4 366 
μg/ml) 48 h post infection over the course of 14 days post-transduction. After selection, successful 367 
knockout was confirmed by immunoblotting. 368 
Statistical analysis. All statistical tests were performed using Graph-Pad Prism version 5.00 369 
for Windows (GraphPad Software). The data are presented as mean ± standard deviation (SD). For 370 
comparisons consisting of two groups, means were compared using two tailed Student’s t tests. 371 
Differences were considered statistically significant at a P value of < 0.05. 372 
 373 
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 561 
FIGURE LEGENDS 562 
FIG 1 Pharmacological inhibition of the H3K9-specific histone methyltransferase SUV39H1 563 
decreases heterochromatin in hrHPV-transformed cells.  (A) Transcript levels of the indicated genes 564 
were assessed by qPCR, and values were normalized to those for GAPDH, with NIKS value set to 565 
1. Data are presented as mean values of biological triplicates. Error bars indicate SD *P < 0.05; **P 566 
< 0.01 (unpaired t test). (B) NIKS, NIKSmcHPV18, HeLa and CaSki total cell extracts were 567 
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subjected to immunoblot analysis with anti-SUV39H1 and anti-tubulin antibodies. The 568 
densitometry values of SUV39H1 were normalized to those of tubulin. Values are representative of 569 
three independent experiments. Error bars indicate SD *P < 0.05; **P < 0.01 (unpaired t test). (C) 570 
NIKS, HeLa and CaSki cells were treated with chaetocin (150 nM) or vehicle (DMSO). After 24 h, 571 
transcript levels of the indicated genes were assessed by qPCR, and the values were normalized to 572 
those for GAPDH, with each vehicle-treated value set to 1. Data are presented as mean values of 573 
biological triplicates. Error bars indicate SD *P< 0.05; **P< 0.01 (unpaired t test). (D) NIKS, 574 
HeLa, and CaSki cells were treated with chaetocin (150 nM) or vehicle (DMSO). After 24 h, total 575 
cell extracts were subjected to immunoblot analysis with anti-RIG-I, cGAS, STING, and anti-576 
tubulin antibodies. The intensities of the bands for each antibody were quantified by densitometry, 577 
and ratios of the abundance of these proteins relative to that of tubulin were calculated. Values are 578 
representative of three independent experiments. Error bars indicate SD *P < 0.05; **P < 0.01 579 
(unpaired t test). (E) Extracts were prepared from HeLa or (F) CaSki cells treated for 24 h with 580 
chaetocin (150 nM) or vehicle (DMSO). ChIP assay was carried out using antibodies specific for 581 
unmodified histone H3 (PAN-H3), trimethylated lysine 4 of H3 (H3K4me3), dimethylated lysine 9 582 
of H3 (H3K9me2), trimethylated lysine 9 of H3 (H3K9me3), trimethylated lysine 27 of H3 583 
(H3K27me3), or IgG as control. Immunoprecipitated promoter sequences were measured by qPCR, 584 
and CT values for the samples were equated to input CT values. Values are represented as relative 585 
binding activity from three independent experiments. Error bars indicate SD *P < 0.05; **P < 0.01 586 
(unpaired t test).  587 
FIG 2 Pharmacological and genetic inhibition of SUV39H1 activity restores IFN production upon 588 
poly(dA:dT) transfection in HPV-transformed cells. (A) ELISA quantitation of IFNβ and IFNλ1 589 
protein in supernatants from cells treated with chaetocin (150 nM) or vehicle (DMSO) for 6 h and 590 
mock-transfected or transfected with poly(dA:dT) for 24 h. Data are presented as mean values of 591 
biological triplicates. Error bars indicate SD *P < 0.05; **P < 0.01 (unpaired t test). (B) Acid 592 
extracts from SUV39H1-deficient (KO) HeLa and CaSki or wild type (WT) cells were subjected to 593 
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immunoblot analysis with anti-SUV39H1, anti-H3K9me3, anti-H3K27me3 or anti-PAN-H3 594 
antibodies. The densitometry values of protein bands were normalized to those of PAN-H3. Values 595 
are representative of three independent experiments. Error bars indicate SD *P < 0.05; **P < 0.01 596 
(unpaired t test). (C) Transcript levels of the indicated genes were assessed by qPCR in cells 597 
described in panel B, and values were normalized to those of GAPDH, with WT mock-transfected 598 
cells value set to 1. Data are presented as mean values of biological triplicates. Error bars indicate 599 
SD *P < 0.05 (unpaired t test). (D) HeLa and CaSki SUV39H1 KO or control cells were subjected 600 
to immunoblot analysis with anti-RIG-I, cGAS, STING or anti-tubulin antibodies. The 601 
densitometry values of protein bands were normalized to those of tubulin. Values are representative 602 
of three independent experiments. Error bars indicate SD *P < 0.05 (unpaired t test). (E) ELISA 603 
quantitation of IFNβ and IFNλ1 protein in supernatants from HeLa and CaSki SUV39H1 KO or 604 
control cells mock-transfected or transfected with poly(dA:dT) for 24 h. Data are presented as mean 605 
values of biological triplicates. Error bars indicate SD *P < 0.05 (unpaired t test).  606 
FIG 3 The HPV E7 oncoprotein regulates SUV39H1 expression levels. (A) Diagrams of HPV16 607 
and HPV18 E6 and E7 ORFs (boxes with E6 and E7 labels) and bicistronic pre-mRNA transcripts 608 
with exons (boxes) and introns (lines between boxes). Numbers above the ORFs and bicistronic 609 
transcripts are nucleotide positions in each viral genome. Red boxes indicate siRNA oligo target 610 
sites. (B)Total extracts from HeLa or CaSki cells transfected with siE6/E7#1, siE6/E7#2 or siCtrl for 611 
72 h were subjected to immunoblot analysis with anti-E6, anti-E7 or anti-tubulin, and acid extracts 612 
from the same set of samples were probed with anti-SUV39H1, anti-H3K9me3 or anti-PAN-H3. 613 
Densitometry values of protein bands were normalized to those of PAN-H3 (acid extracts) or 614 
tubulin (total extracts). Values are representative of three independent experiments. Error bars 615 
indicate SD *P < 0.05 (unpaired t test). (C) Transcript levels of the SUV39H1 were assessed by 616 
qPCR in the cells described in panel B. Values were normalized to those of GAPDH, with siCtrl 617 
value set to 1. Data are presented as mean values of biological triplicates. Error bars indicate SD *P 618 
< 0.05; **P < 0.01 (unpaired t test). (D) Transcript levels of the indicated genes were assessed by 619 
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qPCR in HeLa (upper panels) or CaSki cells (lower panels) transfected with siE6/E7#1, siE6/E7#2 or 620 
siCtrl for 48 h and then mock-transfected or transfected with poly(dA:dT) for 24 h. Values were 621 
normalized to those of GAPDH, with siCtrl-mock-transfected cells value set to 1. Values are 622 
representative of three independent experiments. Error bars indicate SD *P < 0.05; **P < 0.01 623 
(unpaired t test). (E) ELISA quantification of IFNβ and IFNλ1 protein in supernatants from the cells 624 
described in panel B, mock-transfected or transfected with poly(dA:dT) for 24 h. Data are presented 625 
as mean values of biological triplicates. Error bars indicate SD *P < 0.05; **P < 0.01 (unpaired t 626 
test). (F) Total or acid extracts from HEK293 cells transfected with pCI-neo, pCI-neo HPV18 E6, 627 
pCI-neo HPV18 E7, pCI-neo HPV16 E6 or pCI-neo HPV16 E7 for 72 h were subjected to 628 
immunoblot analysis with anti-E6, anti-E7 or anti-tubulin antibodies (all total extracts), while anti-629 
SUV39H1, anti-H3K9me3 or anti-PAN-H3 were used for acid extracts. Densitometry values of 630 
protein bands were normalized to those of PAN-H3 (acid extracts) or tubulin (total extracts). Values 631 
are representative of three independent experiments. Error bars indicate SD *P < 0.05 (unpaired t 632 
test). (G) Transcript levels of the SUV39H1 were assessed by qPCR in HEK293 cells transfected 633 
with pCI-neo, pCI-neo HPV18 E6, pCI-neo HPV18 E7, pCI-neo HPV16 E6 or pCI-neo HPV16 E7 634 
for 72 h. Values were normalized to those of GAPDH, with pCI-neo-transfected value set to 1. Data 635 
are presented as mean values of biological triplicates. Error bars indicate SD *P < 0.05 (unpaired t 636 
test). (H) ELISA quantification of IFNβ and IFNλ1 protein in supernatants from the cells described 637 
in panels F and G, mock-transfected or transfected with poly(dA:dT) for 24 h. Data are presented as 638 
mean values of biological triplicates. Error bars indicate SD *P < 0.05; **P < 0.01; ***P < 0.001 639 
(unpaired t test).  640 
FIG 4 RIG-I is crucial for the innate immune response in hrHPV-transformed cells. (A) Total 641 
extracts from HeLa and CaSki RIG-I-deficient (RIG-I KO) or wild type (WT) cells, mock-642 
transfected or transfected with poly(dA:dT) for 24 h, were subjected to immunoblot analysis with 643 
anti-RIG-I or anti-tubulin antibodies. One representative Western blot of three independent 644 
triplicates is shown. (B) Transcript levels of IFNβ and IFNλ1 genes were assessed by qPCR in RIG-645 
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I KO HeLa (upper panels) and CaSki (lower panels) or WT cells transfected with siE6/E7#1, 646 
siE6/E7#2 or siCtrl for 48 h and then mock-transfected or transfected with poly(dA:dT) or M8 for 24 647 
h. Values were normalized to those of GAPDH, with siCtrl-mock-transfected cells value set to 1. 648 
Values are representative of three independent experiments. Error bars indicate SD *P < 0.05; **P 649 
< 0.01 (unpaired t test). (C) ELISA quantitation of IFNβ and IFNλ1 protein in supernatants from the 650 
cells described in panel B. Data are presented as mean values of biological triplicates. Error bars 651 
indicate SD *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t test). (D) ELISA quantification of 652 
IFNβ and IFNλ1 protein in supernatants from RIG-I KO HeLa (upper panels) and CaSki (lower 653 
panels) or WT  cells, transfected with siCtrl or siSUV39H1 for 48 h and mock-transfected or 654 
transfected with poly(dA:dT) or M8 for 24 h. Data are presented as mean values of biological 655 
triplicates. Error bars indicate SD *P < 0.05; **P < 0.01; ***P < 0.001, (unpaired t test).  656 
FIG 5 Schematic model representing the impact of SUV39H1 activity on the promoter region of 657 
RIG-I, cGAS, and STING genes under basal conditions or after transfection with poly(dA:dT) or 658 
the RIG-I agonist M8. In the lower panel, the same cellular circuits are illustrated under conditions 659 
where E7 or SUV39H1 are inhibited. 660 





